Cervical Cancer Clinical Trials (as in March 2017)

ENGOT-Cx1/BGOG-cx1

Leading group: BGOG

Clinical Trial Study: A randomized phase II trial of paclitaxel-carboplatin 3-weekly with or without Nintedanib (BIBFI 120) in advanced or recurrent cervical carcinoma (I. Vergote)

Number of patients accrued: 49

Planned number of patients: 120

Participating groups:

AGO, GEICO, MaNGO, MITO, NCRI, NOGGO

 

 

ENGOT-Cx2/CEEGOG/SENTIX

Leading group: CEEGOG

Clinical Trial Study: SENTIX (SENTinel lymph node in cervIX cancer) - a prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer

Number of patients accrued: 47

Planned number of patients: 300

Participating groups:

BGOG

 

 

ENGOT-Cx3/CEEGOG/ABRAX

Leading group: CEEGOG

Clinical Trial Study: Abandoning of radical hysterectomy in cervical cancer - retrospective trial

Number of patients accrued: N.A.

Planned number of patients: N.A.

Participating groups: under discussion

 

 

ENGOT-Cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Number of patients accrued: N.A.

Planned number of patients: 900

Participating groups: under discussion

Planned start date end of 2017